S*X
2 楼
Bpax？ 一庄股，小心风险
w*w
3 楼
好危险
t*u
4 楼
我8月前只做 BIOTECH. 现在全仍了.
觉得BIOTECH在现在的大环境下很难飞.
过段时间再搞.
【在 w*w 的大作中提到】
: anyone recommends？？？？
觉得BIOTECH在现在的大环境下很难飞.
过段时间再搞.
【在 w*w 的大作中提到】
: anyone recommends？？？？
w*w
5 楼
方便说下之前都关注了哪些biotech stocks？
【在 t**u 的大作中提到】
: 我8月前只做 BIOTECH. 现在全仍了.
: 觉得BIOTECH在现在的大环境下很难飞.
: 过段时间再搞.
t*u
6 楼
找KEEPBUYING去问.
我搞的8月份后没几个还活着, ANX, BPAX, ALXA, VRTX, ARIA, SEGN,ACUR, PATH, ...
【在 w*w 的大作中提到】
:
: 方便说下之前都关注了哪些biotech stocks？
我搞的8月份后没几个还活着, ANX, BPAX, ALXA, VRTX, ARIA, SEGN,ACUR, PATH, ...
【在 w*w 的大作中提到】
:
: 方便说下之前都关注了哪些biotech stocks？
l*6
7 楼
How about OPTR. I bought 1000s around $8.0 but sold so early at $9.50.
S*X
8 楼
..
B字头活得不错啊，也许快飞了？ 也许。。
另一个大环境是PFE手握600亿现金，但是不快速收购的话，明后年就要变垃圾？
【在 t**u 的大作中提到】
: 找KEEPBUYING去问.
: 我搞的8月份后没几个还活着, ANX, BPAX, ALXA, VRTX, ARIA, SEGN,ACUR, PATH, ...
t*u
9 楼
OPTR药批了, 价格主要看公司收入, 这方面我不懂, 我只搞那些药还没有被FDA批准的.
【在 l******6 的大作中提到】
: How about OPTR. I bought 1000s around $8.0 but sold so early at $9.50.
【在 l******6 的大作中提到】
: How about OPTR. I bought 1000s around $8.0 but sold so early at $9.50.
t*u
10 楼
说8月份出INTERIM RESULT, 我最近没搞BPAX, 就是怕出个坏结果. 胆小了把, 现在都9
月了, 还没见到结果. 不过我估计BPAX的提高女性性趣的药估计要失败.
【在 S****X 的大作中提到】
:
: ..
: B字头活得不错啊，也许快飞了？ 也许。。
: 另一个大环境是PFE手握600亿现金，但是不快速收购的话，明后年就要变垃圾？
月了, 还没见到结果. 不过我估计BPAX的提高女性性趣的药估计要失败.
【在 S****X 的大作中提到】
:
: ..
: B字头活得不错啊，也许快飞了？ 也许。。
: 另一个大环境是PFE手握600亿现金，但是不快速收购的话，明后年就要变垃圾？
S*X
11 楼
都9
没有吧？ 8月29有效性试验结束，一直都是schedule是12月公布结果哈。会安排在11月
NDA结果之后公布吧，万一药没批，libigel phase III 结果还能救救命。 而且,8月
12-20大量的inside buy， 因此估计至少1个半月到2月内， 不会有重要消息公布的。
【在 t**u 的大作中提到】
: 说8月份出INTERIM RESULT, 我最近没搞BPAX, 就是怕出个坏结果. 胆小了把, 现在都9
: 月了, 还没见到结果. 不过我估计BPAX的提高女性性趣的药估计要失败.
t*u
12 楼
Interim result will be checked every 3 months according to seekingalpha news.
There was an interim in May, but the result was reported in June. So there
should be an interim in August. But I don't know when the result will be
disclosed. But there should be no worry about the interim safety results.
============
Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
by: Kaushik Paul
May 10, 2011 | about: BPAX
By May 2011, an independent Data Monitoring Committee (DMC) is expected to
review the Phase III safety trial data of BioSante Pharmaceuticals, Inc.'s (
BPAX) Libigel, ....
In February 2011, during the fifth independent DMC review of the Phase III
trials of the drug, .....
After the fifth independent DMC review, it was decided that additional
safety reviews would be conducted by the independent DMC every 90
days, thus scheduling the next independent DMC to occur in May 2011.
【在 S****X 的大作中提到】
:
: 都9
: 没有吧？ 8月29有效性试验结束，一直都是schedule是12月公布结果哈。会安排在11月
: NDA结果之后公布吧，万一药没批，libigel phase III 结果还能救救命。 而且,8月
: 12-20大量的inside buy， 因此估计至少1个半月到2月内， 不会有重要消息公布的。
There was an interim in May, but the result was reported in June. So there
should be an interim in August. But I don't know when the result will be
disclosed. But there should be no worry about the interim safety results.
============
Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
by: Kaushik Paul
May 10, 2011 | about: BPAX
By May 2011, an independent Data Monitoring Committee (DMC) is expected to
review the Phase III safety trial data of BioSante Pharmaceuticals, Inc.'s (
BPAX) Libigel, ....
In February 2011, during the fifth independent DMC review of the Phase III
trials of the drug, .....
After the fifth independent DMC review, it was decided that additional
safety reviews would be conducted by the independent DMC every 90
days, thus scheduling the next independent DMC to occur in May 2011.
【在 S****X 的大作中提到】
:
: 都9
: 没有吧？ 8月29有效性试验结束，一直都是schedule是12月公布结果哈。会安排在11月
: NDA结果之后公布吧，万一药没批，libigel phase III 结果还能救救命。 而且,8月
: 12-20大量的inside buy， 因此估计至少1个半月到2月内， 不会有重要消息公布的。
S*X
13 楼
news.
(
这个啊。。周一会议上CEO说10月7号公布。 这种中期结果一般问题不大，只要公司愿
意把结果做好看就可以。反正批不批在FDA。
【在 t**u 的大作中提到】
: Interim result will be checked every 3 months according to seekingalpha news.
: There was an interim in May, but the result was reported in June. So there
: should be an interim in August. But I don't know when the result will be
: disclosed. But there should be no worry about the interim safety results.
: ============
: Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
: by: Kaushik Paul
: May 10, 2011 | about: BPAX
: By May 2011, an independent Data Monitoring Committee (DMC) is expected to
: review the Phase III safety trial data of BioSante Pharmaceuticals, Inc.'s (
w*w
14 楼
要慎重慎重
t*u
15 楼
It depends how the interim analysis was prespecified. There should be no
problem for this BPAX study.
Several companies (e.g. AIS) reported nice phase 3 result in August, but
there is little effect on the stock price. That is why I feel it is not a
good time to buy small pharm now.
【在 S****X 的大作中提到】
:
: news.
: (
: 这个啊。。周一会议上CEO说10月7号公布。 这种中期结果一般问题不大，只要公司愿
: 意把结果做好看就可以。反正批不批在FDA。
problem for this BPAX study.
Several companies (e.g. AIS) reported nice phase 3 result in August, but
there is little effect on the stock price. That is why I feel it is not a
good time to buy small pharm now.
【在 S****X 的大作中提到】
:
: news.
: (
: 这个啊。。周一会议上CEO说10月7号公布。 这种中期结果一般问题不大，只要公司愿
: 意把结果做好看就可以。反正批不批在FDA。
j*7
16 楼
垃圾药, 过了又能怎样.
【在 S****X 的大作中提到】
:
: news.
: (
: 这个啊。。周一会议上CEO说10月7号公布。 这种中期结果一般问题不大，只要公司愿
: 意把结果做好看就可以。反正批不批在FDA。
【在 S****X 的大作中提到】
:
: news.
: (
: 这个啊。。周一会议上CEO说10月7号公布。 这种中期结果一般问题不大，只要公司愿
: 意把结果做好看就可以。反正批不批在FDA。
相关阅读